Piramal's subsidiary gets encouraging results in detection of beta-amyloid

16 Apr 2012 Evaluate

Piramal Imaging SA (Piramal), a newly formed subsidiary of Piramal Healthcare has received positive results from a Phase III study that showed that PET imaging with florbetaben reliably detects beta-amyloid in the brain during life with great accuracy and thus shows value as a potential tool to aid in the diagnosis and assessment of Alzheimer’s disease. The study results will be featured as part of the Emerging Science Program on April 25, 2012 at the American Academy of Neurology’s 64th Annual Meeting in New Orleans.

The only way to definitively diagnose Alzheimer’s disease has been after death - at autopsy - through analysis and identification of beta-amyloid in brain tissue. The global Phase III trial employed a unique and rigorous study design comparing in vivo brain PET imaging with florbetaben to post-mortem analysis of the brain tissue.

Besides, Piramal has signed an agreement to acquire worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma AG through its newly created subsidiary - Piramal Imaging SA. Florbetaben is the lead compound in the portfolio.

Piramal Healthcare is one of the largest custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries.

Piramal Enterprises Share Price

950.35 -37.15 (-3.76%)
13-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Bajaj Finance 7147.10
Shriram Finance 520.80
Aditya Birla Capital 169.70
SBI Cards AndPayment 712.85
Mah & Mah Finl. Serv 262.95
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.